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Novel Nonsense Mutation (p.Y113X) in the Human 
Growth Hormone Receptor Gene in a Brazilian
Patient with Laron Syndrome
ABSTRACT
Background: To date, about sixty different mutations within GH receptor (GHR) 
gene have been described in patients with GH insensitivity syndrome (GHI). In 
this report, we described a novel nonsense mutation of GHR. Methods: The pa-
tient was evaluated at the age of 6 yr, for short stature associated to clinical phe-
notype of GHI. GH, IGF-1, and GHBP levels were determined. The PCR products 
from exons 2–10 were sequenced. Results: The patient had high GH (26 µg/L), 
low IGF-1 (22.5 ng/ml) and undetectable GHBP levels. The sequencing of GHR 
exon 5 disclosed adenine duplication at nucleotide 338 of GHR coding sequence 
(c.338dupA) in homozygous state. Conclusion: We described a novel mutation 
that causes a truncated GHR and a loss of receptor function due to the lack of 
amino acids comprising the transmembrane and intracellular regions of GHR 
protein, leading to GHI. (Arq Bras Endocrinol Metab 2008; 52/8:1264-1271)
Keywords: Growth hormone insensitivity; Somatotropin receptors; Genetics; 
Growth
RESUMO
Nova Mutação Nonsense (p.Y113X) no Gene do Receptor do Hormônio do 
Crescimento em um Paciente Brasileiro com Síndrome de Laron.
Introdução: Até o momento, aproximadamente 60 diferentes mutações envol-
vendo o gene do receptor do GH (GHR) foram descritas em pacientes com a 
síndrome de insensibilidade ao GH (GHI). Neste artigo, descrevemos uma nova 
mutação nonsense do GHR. Métodos: O paciente foi avaliado aos 6 anos de 
idade para baixa estatura associada ao fenótipo clínico da GHI. Níveis de GH, 
IGF-1 e GHBP foram determinados. Os produtos de PCR dos éxons 2-10 foram 
seqüenciados. Resultados: O paciente apresentou níveis elevados de GH (26 
µg/L), baixos de IGF-1 (22.5 ng/ml) e indetectáveis de GHBP. O seqüenciamento 
do éxon 5 do GHR revelou uma duplicação da adenina no nucleotídeo 338 da 
sequência de codifi cação do GHR (c.338dupA) em homozigose. Conclusão: 
Descrevemos uma nova mutação que causa um GHR truncado e uma perda da 
função do receptor devido à perda de aminoácidos compreendendo as regiões 
transmembrana e intracelular do receptor, levando a GHI. (Arq Bras Endocrinol 
Metab 2008; 52/8:1264-1271)
Descritores: Insensibilidade ao hormônio do crescimento; Receptores do 
hormônio do crescimento; Genética; Crescimento
INTRODUCTION
The Laron syndrome (LS) is a genetic disorder defi ned as the inability to res-pond to endogenous or exogenous GH with appropriate growth and meta-
bolic effects. It is caused by defects in the GH receptors (GHR). Clinically, growth 
hormone insensitivity (GHI) is characterized by severe growth failure after birth, 
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craniofacial disproportion, elevated serum GH and low 
IGF-I that failed to respond to GH (1-3).
LS is caused, in most cases, by a fully penetrant au-
tosomal recessive mechanism leading to genetic defects 
along the GH-IGF axis, including the GHR. The GHR 
gene on the short arm of chromosome 5 includes 9 
exons comprising 620 amino acid residues in its mature 
form. The GHR protein can be divided into the extra-
cellular domain (encoded by exons 2–7), the transmem-
brane domain (encoded by exon 8), and the intracellular 
domain (encoded by exons 9 and 10) (4,5).
The fi rst genetic defect of the GHR described was 
a deletion of exons 5 and 6 which encode a large extra-
cellular GH-binding domain. Since then, about sixty 
mutations of the GHR gene have been described (6).
Ethnic origin of reported cases is predominantly 
Middle Eastern, Mediterranean, South Asian and Ecu-
adorian. In Brazil twelve patients with the LS have been 
reported so far, including six children from Orobó 
(Pernambuco state) carrier of the E180 splice site mu-
tation (7). Another case, also from Pernambuco (city of 
Recife), was described in 1997 (8) and, in this paper, a 
novel mutation in the exon 5 of GHR in this patient is 
described for the fi rst time.
SUBJECTS AND METHODS
Case report
The patient was evaluated for short stature, soon after 
adoption. Birth length was 44 cm and weight 3 kg. At the 
age of 6.5 years, his height was 77 cm [height standard 
deviation score (SDS) –8.0], weigh 9 kg [90% of ideal 
body weight for height (IBW)] and bone age of 3 years.
When he was 10 yr 9 mo of age, he was reevaluated 
and measured 86 cm in height (height SDS –8.8) and 
weighed 12 kg (100% IBW). At 12 years of age his 
height was 87.8 cm (height SDS -8.4) and his weight 
11.1 kg (89% IBW). Head circumference was 49.1cm, 
25th percentile for his height (ie normal head circum-
ference for 24 months).
He had facial asymmetry, prominent forehead, de-
pressed nasal bridge, short vertical dimension of the 
face, microstomia and blue sclerae. There was severe 
dental crowding and caries of retained primary denti-
tion. His voice was high pitched. There was limited el-
bow extension of approximately 5 degrees bilaterally. 
Stretched penile length was 4 cm (10th percentile for 
age 3) and the testes were 1mL bilaterally.
After the diagnosis of GHI, he was treated with hu-
man recombinant IGF-I (Genentech, South San Fran-
cisco, CA) at a dosage of 100μg/kg/body weight twice 
daily by subcutaneous injection. During the subsequent 
6 months he grew 3.1 cm at the rate of 6 cm/year. 
Hormonal studies
The GH was determined by quimioluminescence (Im-
mulite-DPC 2000). The assay was calibrated against 
WHO IRP 80/505 and recognized 22 kDa GH iso-
form; interassay coeffi cient of variation was 4,6%. The 
IGF-1 and IGFBP-3 were measured using immunora-
diometric assay (Immulite-DPC 2000) and interassay 
coeffi cient of variation were 3,9 e 4,8%, respectively. 
The GHBP was determined by ligand-mediated immu-
nofunctional assay (LIFA; Esoterix, Austin, TX, USA).
IGF-1 generation test involved daily injections of 
recombinant human GH (0,1 U/kg subcutaneously) 
for 4 days. Blood samples were drawn in the morning 
before the fi rst injection and 12 hours after the last 
dose. IGF-1 increase < 15 µg/L was considered for the 
diagnosis of GHI.
Molecular studies 
Genomic DNA was isolated from peripheral blood leu-
cocytes from the patient and 50 normal height con-
trols. We studied the GHR gene of the patient, 
amplifying exons 2–9 using specifi c intronic primers 
and exon 10 in three overlapping fragments to cover 
the entire coding region.
PCR was carried out in a 25-µl mixed solution, 
containing 50-200 ng genomic DNA, 20 pmol/L each 
pair of primers, 0.2 mmol/L each of deoxy-ATP, -GTP, 
-CTP, -TTP, 1.5 to 4.0 mmol MgCL2, 0.5 U Taq DNA 
polymerase, 50 mmol/l KCl, 10 mmol/l Tris-HCl (pH 
8.3) (Table 1). PCR involved initial denaturation step 
for 5 min at 95 oC, 35 cycles of denaturation for 1 min 
at 94 oC, primer annealing for 1 min at 55 C, and prim-
er extension for 1 min at 72 C, followed by a fi nal ex-
tension step for 10 min at 72 C in a thermal-cycler. 
PCR products were viewed after electrophoresis on 2% 
(wt/vol) agarose gel stained with ethidium bromide 
and photographed under UV light. PCR products from 
exons 2–10 were directly sequenced with dideoxy 
chain-termination method using a kit ABI PrismTM 
BigDye Terminator (Perkin Elmer, Foster City, CA, 
USA) and analysed by an autosequencer ABI Prism Ge-
netic Analyser 3100 automatic DNA sequencer (Perkin 
Elmer). Exon 5 of 50 control samples were amplifi ed 
by PCR and directly sequenced.
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Table 1. Primer pairs to amplify the GHR coding sequence, sizes of PCR products and fi nal MgCl2 concentration for PCR reaction.
Exon Primer PCR product (bp) [MgCl2]
2 Sense: 5’ TTTCATGATAATGGTCTGCT 3’ 193 1.5 mM
Antisense: 5’ GAATACAGTTCAGTGTTGTTT 3’ 
3 Sense: 5’ GATGGACTAGATGGTTTTGCCTTCCTCTTTCTGTTTCAG 3’ 100 1.5 mM
Antisense: 5’ GGATAGTAGCTTAATTACAC 3’ 
4 Sense: 5’ AGGATCACATATGACTCACC 3’ 231 2.5 mM
Antisense: 5’ AGGAAAATCAGAAAGGCATG 3’ 
5 Sense: 5’ ACTTAAGCTACAACATGATT 3’ 274 4.0 mM
Antisense: 5’ GCTTCCCCATTTATTTAGT 3’ 
6 Sense: 5’ ATTGTGTCTGTCTGTGTACTAATG 3’ 247 1.5 mM
Antisense: 5’ ATAGAAAGAAAAGTCAAAGTGTAAG 3’ 
7 Sense: 5’ TAGTGTTCATTGGCATTGAG 3’ 328 3.0 mM
Antisense: 5’ ACAAAAGCCAGGTTAGCTAC 3’ 
8 Sense: 5’ GAAACTGTGCTTCAACTAGTC 3’ 205 4.0 mM
Antisense: 5’ GGTCTAACACAACTGGTACA 3’ 
9 Sense: 5’ GCTATAATTGAGAATATGTAG 3’ 204 1.5 mM
Antisense: 5’ CATATGACAGGAGTCTTCAGGTG 3’ 
10 Sense: 5’ GAGTTTCTTTTCATAGATCTTCATTTTC 3’ 1.150 1.5 mM
Antisense: 5’ GGTTTAAACATTGTTTTGGC 3’ 
A*: 5’ GTTGCTCAGCCACAGAGGTT 3’
B*: 5’ CCAGCAGGTAGTGTGGTCCT 3’
* primers used only for sequence.
RESULTS
Hormonal results
During insulin-induced hypoglycemia stimulation test, 
GH rose from a high baseline of 26 µg/L to 52 µg/L 
at 45 minutes. IGF-I level was low at 22.5 ng/ml (nor-
mal for age: 80-650 ng/ml) and the IGFBP-3 level was 
also low at 100 ng/ml (normal for age: 2000-6000 
ng/ml). After exogenous GH injection (0.1U/kg/
day) for 4 days, the serum IGF-I was 24ng/dl.
At the age of 12 years, he was evaluated at the Uni-
versity of North Carolina to entry into a treatment pro-
gram with recombinant IGF-I injections and was found 
to have an IGF-I level in serum of <10 ng/ml, and a 
GH level of 22 µg/L. After 4 days of GH injections 
(0.1 U/kg/day), there was no change in IGF-I serum 
concentration. The serum concentration of GH-bind-
ing protein (GHBP) was undetectable (<140 pmol/l; 
normal for ages 10-15 yr, 431-1892 pmol/l).
Molecular results 
Direct sequence of GHR exon 5 (DNA reference se-
quence: NM_000163) disclosed an adenine duplica-
tion at nucleotide 338 of the GHR coding sequence 
(c.338dupA) and was observed in homozygous state in 
the patient`s genomic DNA. This allelic variant was not 
found in 100 alleles from the control group and causes 
a nonsense mutation through the conversion of tyrosine 
(TAC) into a premature termination signal (TAA) (p.
Y113X). This stop codon occurs in the extracellular do-
main and produces a truncated GHR that would be 
unable to exhibit receptor function, due to the lack of 
525 amino acids comprising the transmembrane and 
intracellular regions of GHR protein.
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DISCUSSION
Growth hormone insensitivity (GHI) is a rare disorder 
and 12 Brazilian patients have been reported to date 
(7), including the present patient (8). All these patients 
presented with the typical clinical features of LS with 
elevated serum GH, low IGF-I which failed to respond 
to GH, and low GHBP.
Among Brazilian GHI patients, molecular studies 
were conducted in 6 cases, and all of them presented ho-
mozygous mutations in GHR gene. The fi rst two GHI 
cases reported from Brazil were homozygous for a substi-
tution of T for G at the -1 position of the 3’ splice consen-
sus sequence of intron 6 (c.619-1 G>C) (9, 10). Another 
patient carried a homozygous mutation, replacing serine 
by isoleucine in codon 244 of exon 7 (p.S244I) (11). The 
last six patients described in Brazil were also from Per-
nambuco and carried a homozygous replacement of gua-
nine by adenine in codon 198 of exon 6 (c.594 A>G), 
creating an abnormal splice site deleting 8 amino acids 
from the extracellular domain of GHR (p.V199_M206del) 
(7). To date, this is the most common mutation present in 
Brazil, as well as in the world. The mutation in codon 
198, also known as E180Splice mutation, has been de-
scribed in Ecuadorian patients and two Israeli patients of 
Moroccan descent (12,13).
Finally, in the present study, we describe a novel non-
sense GHR mutation in homozygous state, adenine du-
plication at nucleotide 338 (c.338dupA). This nucleotide 
alteration causes a premature termination signal at con-
don 113 (p.Y113X), predicting a truncated GHR that 
would be unable to exhibit receptor function due to the 
lack of amino acids comprising the transmembrane and 
intracellular regions of GHR protein. This molecular 
fi nding is in accord with undetectable levels of GHBP 
observed in our patient. GHBP is a product of prote-
olytic cleavage of the extracellular domain of GHR and 
is typically absent or present at low levels in patients with 
GHI, refl ecting failure of GH receptor synthesis (14).
To date, approximately 60 GHR defects have been 
described, such as gross deletions, missense, nonsense, 
frameshift, and splice site mutations. Fourteen nonsense 
mutations in GHR were described (Table 2), being 2 of 
them located in exon 5 (22,23).
Table 2A. Standard and colloquial nomenclature for GHR mutations (Gross Deletion and Nonsense mutations).
Type of Mutation DNA sequencechange*
Site of 
mutation
Amino acid 
change
Colloquial 
nomenclature Reference
Deletion
~ 1.2 kb deletion Partial Exon 5 
deletion 
(15)
~ 4 kb deletion Exon 5 (16)
~ 19 kb deletion Exon 5-6 (17)
del(5) p11-p13.1 Exon 4-10 (18)
Nonsense
c.12 G>A Exon 2 p.W4X W15X (19)
c.101 G>A Exon 3 p.W34X W16X (20)
c.168 C>A Exon 4 p.C56X C38X (21)
c.181 C>T Exon 4 p.R61X R43X (21)
c.247 C>T Exon 4 p.Q83X Q65X (22)
c.293 G>A Exon 5 p.W98X W80X (22)
c.303 C>A Exon 5 p.C101X C83X (23)
c.338 dupA Exon 5 p.Y113X Y97X #
c.476 T>A Exon 6 p.L159X L141X (19)
c.524 G>A Exon 6 p.W175X W157X (22)
c.601 G>T Exon 6 p.E201X E183X (13)
c.703 C>T Exon 7 p.R235X R217X (24)
c.724 G>T Exon 7 p.E242X E224X (25)
c.744 delT Exon 7 p.Y248X 230delT (26)
# present study
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years before any mutation nomenclature recommenda-
tions were proposed. Therefore, published and com-
monly used designations for many GHR mutations 
have been at variance with the evolving standard no-
menclature guidelines (43). In Table 1, we reviewed all 
GHR mutations and disclosed the standard nomencla-
ture and colloquial nomenclature side by side. Nucle-
otide numbering is based on cDNA reference sequence 
(NM_000163) and amino acid numbering is based on 
GHR protein reference (NP_000154), being the trans-
lation initiator Methionine numbered as +1 codon, in 
contrast to the colloquial notations that numbered the 
ATG initiation codon as -18. 
GHR mutations are concentrated in extracellular 
domain, mainly in exons 4, 5, 6 and 7; whereas muta-
tions in the exons 8, 9 and 10 are rare (Table 1). Al-
though there are rare cases of autosomal dominant 
inheritance, the majority of cases of GHI are caused by 
an autosomal recessive mechanism or exhibit com-
pound heterozygous defects. Most cases are associated 
with parental consanguinity (4,14,44), but such data 
are not available for this patient.
Table 2B. Standard and colloquial nomenclature for GHR mutations (Frameshift and splice site mutations).
Frameshift
c.162delC Exon 4 p.K55fsX79 162delC (22)
c.192_193delTT Exon 4 p.S65fsX70 46delTT (9)
c.421_422dupTT Exon 5 p.L143fs147 422insTT (6)
c.743_744delAT Exon 7 p.Y248fs259 230 del AT (9)
c.889_911del Exon 9 p.I297fs299 889-911del (27)
c.981delC Exon 10 p.I328fs348 981delC (25)
c.1324_1345del Exon 10 p.A442fs478 GHR(1-499) (28)
c.1734delG Exon 10 p.R578fs600 1776 del G (23)
Splice
c.594 A>G Exon 6 p.V199_M206del E180Splice (29)
c.723 C>T Exon 7 G236Splice (22,30)
c.875 G>C Exon 8 p.R292T R274T (31)
c.70+1 G>A Intron 2 70+1 G>A (22)
c.266+1 G>A Intron 4 71+1 G>A (9)
c.440-1 G>C Intron 5 IVS5 -1 G>C (24)
c.618+1.8kb A>G Intron 6 ψ6 (32)
c.619-1 G>T Intron 6 189-1G>T (9)
c.619-1 G>C Intron 6 189-1G>C (33)
c.619-25 A>G Intron 6 IVS 6 -25 A>G (29)
c.785-1 G>T Intron 7 785-1 G>T (34)
c.876-1 C>G Intron 8 GHR(1-277) (35)
c.945+1 G>A Intron 9 GHR(1-277) (36)
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Table 2C. Standard and colloquial nomenclature for GHR mutations (Misense mutation and others).
Missense
c.1 A>T Exon 2 p.0? M-18L (37)
c.166 T>A Exon 4 p.C56S C38S (22)
c.173 C>T Exon 4 p.S58L S40L (22)
c.148 G>A Exon 4 p.E60K E42K (38)
c.202 T>C Exon 4 p.W68R W50R (22)
c.266 G>A Exon 4 p.R89K R71K (24)
c.310 T>G Exon 5 p.Y104D Y86D (26)
c.335 G>C Exon 5 p.C112S C94S (4)
c.341 T>C Exon 5 p.F114S F96S (39)
c. 428 T>C Exon 5 p.V143A V125A (24)
c.446 C>A Exon 6 p.P149Q P131Q (40)
c.485 T>A Exon 6 p.V162D V144D (24)
c.504 T>G Exon 6 p.H168Q H150Q (4)
c.508 G>C Exon 6 p.D170H D152H (41)
c.512 T>C Exon 6 p.I171T I153T (27)
c. 515 A>C Exon 6 p.Q172P Q154P (27)
c. 518 T>G Exon 6 p.V173G V155G (27)
c.535 C>T Exon 6 p.R179C R161C (24)
c.685 C>G Exon 7 p.R229G R211G (24)
c.731 G>T Exon 7 p.S244I S226I (11)
c.677 A>G Exon 7 p.Y226C Y208C (42)
c.784 G>A Exon 7 p.D262N D244N (42)
* Nucleotide numbering is based on DNA reference sequence NM_000163. Number nucleotides and name mutations or variants, respectively, according to the 
standard nomenclature recommendations (http://www.HGVS.org/mutnomen/).
Rarely, GHI may also result from mutations in sig-
nal transducer and activator of transcription 5B gene 
(STAT5b; OMIM: 604260), the main component of 
the GH signaling pathway (5). STAT5b also plays an 
important role in signaling within immune cells, thus 
clinical immunodefi ciency is common in patients with 
STAT5b defi ciency, although is not an obligatory phe-
nomenon (4,45,46).
In conclusion, we expand the repertoire of GHR 
mutations describing the novel mutation (c.338dupA; 
p.Y113X) in a Brazilian GHI patient.
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